SignalEU/UK
Novo Nordisk: Better Than It Looks, But Not A Buy Yet
Novo Nordisk analysis suggests better fundamentals than apparent, but not yet a buy.
Context
What happened: An analyst maintained a Hold rating on Novo Nordisk while becoming more optimistic about its longer-term prospects, citing a broader pipeline and franchise strategy.
Key numbers: Q3 revenue growth was driven almost entirely by the Wegovy pill; excluding it, group revenues would have declined by approximately 2%.
Why it matters: Pricing pressure and patent expiry risk remain significant, and the analyst says NVO's future hinges on broadening its drug franchises, notably CagriSema and Zenagamtide, to mitigate semaglutide concentration and pricing risks.
What changed
An analyst maintained a Hold rating on Novo Nordisk while becoming more optimistic about its longer-term prospects, citing a broader pipeline and franchise strategy.
Why it matters
Pricing pressure and patent expiry risk remain significant, and the analyst says NVO's future hinges on broadening its drug franchises, notably CagriSema and Zenagamtide, to mitigate semaglutide concentration and pricing risks.